Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Sung H, Garcia-Closas M, Chang-Claude J, Blows FM, Ali HR, Figueroa J, Nevanlinna H, Fagerholm R, Heikkilä P, Blomqvist C, Giles GG, Milne RL, Southey MC, McLean C, Mannermaa A, Kosma VM, Kataja V, Sironen R, Couch FJ, Olson JE, Hallberg E, Olswold C, Cox A, Cross SS, Kraft P, Tamimi RM, Eliassen AH, Schmidt MK, Bolla MK, Wang Q, Easton D, Howat WJ, Coulson P, Pharoah PD, Sherman ME, Yang XR.
Sung H, et al. Among authors: ali hr.
Br J Cancer. 2016 Feb 2;114(3):298-304. doi: 10.1038/bjc.2015.437. Epub 2015 Dec 17.
Br J Cancer. 2016.
PMID: 26679376
Free PMC article.
Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. ...CONCLUS …
Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth …